JP2013539369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013539369A5 JP2013539369A5 JP2013527309A JP2013527309A JP2013539369A5 JP 2013539369 A5 JP2013539369 A5 JP 2013539369A5 JP 2013527309 A JP2013527309 A JP 2013527309A JP 2013527309 A JP2013527309 A JP 2013527309A JP 2013539369 A5 JP2013539369 A5 JP 2013539369A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 71
- 239000012634 fragment Substances 0.000 claims 49
- 239000000427 antigen Substances 0.000 claims 37
- 102000036639 antigens Human genes 0.000 claims 37
- 108091007433 antigens Proteins 0.000 claims 37
- 102000039446 nucleic acids Human genes 0.000 claims 28
- 108020004707 nucleic acids Proteins 0.000 claims 28
- 150000007523 nucleic acids Chemical class 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 28
- 102000040430 polynucleotide Human genes 0.000 claims 23
- 108091033319 polynucleotide Proteins 0.000 claims 23
- 239000002157 polynucleotide Substances 0.000 claims 23
- 238000006467 substitution reaction Methods 0.000 claims 20
- 239000013598 vector Substances 0.000 claims 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 13
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 11
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 10
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 9
- 239000003937 drug carrier Substances 0.000 claims 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 241000589989 Helicobacter Species 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101100222384 Mus musculus Cxcl13 gene Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000005004 lymphoid follicle Anatomy 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37967210P | 2010-09-02 | 2010-09-02 | |
| US61/379,672 | 2010-09-02 | ||
| US201161481645P | 2011-05-02 | 2011-05-02 | |
| US61/481,645 | 2011-05-02 | ||
| PCT/US2011/050177 WO2012031099A2 (en) | 2010-09-02 | 2011-09-01 | Anti-cxcl13 antibodies and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016218182A Division JP2017099379A (ja) | 2010-09-02 | 2016-11-08 | 抗ｃｘｃｌ１３抗体およびそれを用いる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013539369A JP2013539369A (ja) | 2013-10-24 |
| JP2013539369A5 true JP2013539369A5 (enExample) | 2014-10-16 |
| JP6097690B2 JP6097690B2 (ja) | 2017-03-15 |
Family
ID=45773520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527309A Active JP6097690B2 (ja) | 2010-09-02 | 2011-09-01 | 抗ｃｘｃｌ１３抗体およびそれを用いる方法 |
| JP2016218182A Withdrawn JP2017099379A (ja) | 2010-09-02 | 2016-11-08 | 抗ｃｘｃｌ１３抗体およびそれを用いる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016218182A Withdrawn JP2017099379A (ja) | 2010-09-02 | 2016-11-08 | 抗ｃｘｃｌ１３抗体およびそれを用いる方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9963504B2 (enExample) |
| EP (1) | EP2611832B1 (enExample) |
| JP (2) | JP6097690B2 (enExample) |
| KR (1) | KR101862236B1 (enExample) |
| CN (1) | CN103347896B (enExample) |
| AU (1) | AU2011295902B2 (enExample) |
| BR (1) | BR112013005145B1 (enExample) |
| CA (1) | CA2810217C (enExample) |
| DK (1) | DK2611832T3 (enExample) |
| MX (1) | MX353476B (enExample) |
| NZ (1) | NZ608318A (enExample) |
| SG (1) | SG188285A1 (enExample) |
| WO (1) | WO2012031099A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2427212B1 (en) | 2009-05-08 | 2017-08-23 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| EP2611832B1 (en) | 2010-09-02 | 2017-11-29 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| JP2014505239A (ja) * | 2010-12-14 | 2014-02-27 | モアハウス スクール オブ メディスン | 癌の治療または検出のための抗ｃｘｃｌ１３および抗ｃｘｃｒ５抗体の使用 |
| EA029023B1 (ru) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US9890213B2 (en) | 2012-03-02 | 2018-02-13 | Vaccinex, Inc. | Methods for the treatment of B cell-mediated inflammatory diseases |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| WO2014003742A1 (en) * | 2012-06-27 | 2014-01-03 | Morehouse School Of Medicine | Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation |
| HK1216265A1 (zh) * | 2012-12-07 | 2016-10-28 | Baxalta GmbH | 抗-mif抗體的細胞遷移測定方法 |
| JP6363623B2 (ja) * | 2013-01-31 | 2018-07-25 | ヴァクシネックス， インコーポレイテッド | 免疫グロブリンａのレベルを増大するための方法 |
| CA2902442A1 (en) * | 2013-03-08 | 2014-09-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
| US9243068B2 (en) | 2013-06-25 | 2016-01-26 | Vaccinex, Inc. | Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases |
| EP3349791A1 (en) | 2015-09-15 | 2018-07-25 | Board of Regents, The University of Texas System | T-cell receptor (tcr)-binding antibodies and uses thereof |
| PT3445397T (pt) | 2016-04-22 | 2023-01-13 | Vaccinex Inc | Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus |
| SG11201900595YA (en) | 2016-08-02 | 2019-02-27 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| CN111615520A (zh) * | 2017-12-01 | 2020-09-01 | 辉瑞大药厂 | 抗cxcr5抗体及其组合物和用途 |
| EP3852779A4 (en) * | 2018-09-17 | 2022-06-08 | Abcuro, Inc. | ANTI-KLRG1 ANTIBODIES |
| CA3098509A1 (en) | 2018-09-18 | 2020-03-26 | I-Mab Biopharma Us Limited | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer |
| EP4164745A1 (en) | 2020-06-11 | 2023-04-19 | Vaccinex, Inc. | Use of cxcl13 binding molecules to promote peripheral nerve regeneration |
| CN115975946A (zh) * | 2022-12-01 | 2023-04-18 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 表达趋化因子cxcl10、cxcl13、ccl19的免疫细胞及其制备方法与应用 |
| CN121652269B (zh) * | 2026-02-05 | 2026-04-17 | 北京中杉金桥生物技术有限公司 | 一种抗人cxcl13兔单克隆抗体、制备方法及其应用 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| EP0582595A1 (en) | 1991-04-26 | 1994-02-16 | Surface Active Limited | Novel antibodies, and methods for their use |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US6692920B1 (en) | 1994-12-07 | 2004-02-17 | Incyte Corporation | Antibodies to a chemokine expressed in inflamed adenoid |
| US5633149A (en) | 1994-12-07 | 1997-05-27 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding novel chemokine expressed in inflamed adenoid |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CN1190991A (zh) | 1995-06-05 | 1998-08-19 | 人类基因组科学公司 | 人类趋化因子β－11和人类趋化因子α－1 |
| WO1998011226A2 (en) | 1996-09-10 | 1998-03-19 | Schering Corporation | Mammalian chemokines, related reagents |
| US6852508B1 (en) | 1997-02-28 | 2005-02-08 | Genetics Institute, Llc | Chemokine with amino-terminal modifications |
| US6110695A (en) | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| US20030186889A1 (en) | 2000-03-31 | 2003-10-02 | Wolf-Georg Forssmann | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| GB2361003A (en) | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
| US7052676B2 (en) | 2000-09-26 | 2006-05-30 | The Regents Of The University Of Michigan | Methods for inhibition of HIV replication using a small molecule inhibitor |
| CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
| US20020111290A1 (en) | 2000-12-01 | 2002-08-15 | Bernhard Homey | Uses of mammalian genes and related reagents |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US6818406B2 (en) | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
| US20030020733A1 (en) | 2001-07-24 | 2003-01-30 | Yin Memphis Zhihong | Computer display having selective area magnification |
| US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US7413866B2 (en) | 2001-11-30 | 2008-08-19 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CA2487932A1 (en) * | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| AU2003298607B9 (en) | 2002-10-29 | 2011-08-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7919083B2 (en) | 2002-11-15 | 2011-04-05 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| US7964194B2 (en) | 2002-11-15 | 2011-06-21 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation |
| EP1572116A4 (en) | 2002-11-26 | 2007-12-12 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| CA2520853A1 (en) * | 2003-03-28 | 2005-03-31 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
| EP1570857A1 (en) | 2004-02-27 | 2005-09-07 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Method for inhibiting the transendothelal migration of cells such as leukocytes or tumor cells by a CD81 binding agent and uses thereof |
| WO2005110492A2 (en) * | 2004-04-12 | 2005-11-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of using adenoviral vectors to induce an immune response |
| CA2501422C (en) | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
| AU2005256113B2 (en) * | 2004-07-09 | 2011-02-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| BRPI0518994A2 (pt) * | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| JP5838021B2 (ja) * | 2005-04-15 | 2015-12-24 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| US20070136826A1 (en) | 2005-12-02 | 2007-06-14 | Biogen Idec Inc. | Anti-mouse CD20 antibodies and uses thereof |
| GB0607774D0 (en) | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
| EP2021016B1 (en) * | 2006-04-21 | 2016-01-06 | Janssen Biotech, Inc. | Cxcl-13 antagonists and tnf-alpha antagonists for use in a combination therapy |
| US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
| US20080199481A1 (en) * | 2007-02-21 | 2008-08-21 | Astrazeneca Ab | Compounds |
| AU2008232536A1 (en) * | 2007-03-30 | 2008-10-09 | Centocor, Inc. | CXCL13 antagonists and their use for the treatment of inflammatory diseases |
| US20110300167A1 (en) | 2008-11-04 | 2011-12-08 | Mcmurry Thomas J | Cxcr5 receptor compounds |
| EP2611832B1 (en) | 2010-09-02 | 2017-11-29 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| WO2013102123A2 (en) | 2011-12-28 | 2013-07-04 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
| US9890213B2 (en) | 2012-03-02 | 2018-02-13 | Vaccinex, Inc. | Methods for the treatment of B cell-mediated inflammatory diseases |
| JP6363623B2 (ja) | 2013-01-31 | 2018-07-25 | ヴァクシネックス， インコーポレイテッド | 免疫グロブリンａのレベルを増大するための方法 |
| CA2902442A1 (en) | 2013-03-08 | 2014-09-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
-
2011
- 2011-09-01 EP EP11822655.4A patent/EP2611832B1/en active Active
- 2011-09-01 AU AU2011295902A patent/AU2011295902B2/en active Active
- 2011-09-01 BR BR112013005145-0A patent/BR112013005145B1/pt active IP Right Grant
- 2011-09-01 JP JP2013527309A patent/JP6097690B2/ja active Active
- 2011-09-01 NZ NZ60831811A patent/NZ608318A/en unknown
- 2011-09-01 WO PCT/US2011/050177 patent/WO2012031099A2/en not_active Ceased
- 2011-09-01 US US13/820,278 patent/US9963504B2/en active Active
- 2011-09-01 CN CN201180052932.5A patent/CN103347896B/zh active Active
- 2011-09-01 SG SG2013013735A patent/SG188285A1/en unknown
- 2011-09-01 MX MX2013002495A patent/MX353476B/es active IP Right Grant
- 2011-09-01 CA CA2810217A patent/CA2810217C/en active Active
- 2011-09-01 KR KR1020137008377A patent/KR101862236B1/ko active Active
- 2011-09-01 DK DK11822655.4T patent/DK2611832T3/en active
-
2016
- 2016-11-08 JP JP2016218182A patent/JP2017099379A/ja not_active Withdrawn
-
2018
- 2018-04-13 US US15/953,139 patent/US10829550B2/en active Active
-
2020
- 2020-09-24 US US17/030,627 patent/US11981730B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516057A5 (enExample) | ||
| ES2573115T3 (es) | Nuevo anticuerpo anti-DR5 | |
| JP7041516B2 (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| JP2021518140A5 (enExample) | ||
| JP2018121657A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| JP2013520984A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| RU2018119366A (ru) | Мыши с гуманизированной легкой цепью | |
| JP2012504401A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| JP2020510422A5 (enExample) | ||
| JP2010246565A5 (enExample) | ||
| JP2012525854A5 (enExample) | ||
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| JP2016128474A5 (enExample) | ||
| RU2013153592A (ru) | Анти-mif антитела | |
| JP2012526542A5 (enExample) | ||
| RU2009126766A (ru) | Антитела человека к дельта-подобному лиганду-4 человека | |
| JP2017529067A5 (enExample) | ||
| FI3842456T3 (fi) | Monoklonaalinen interleukiini-31-vasta-aine | |
| HRP20150965T1 (hr) | Anti-fgr3 protutijela i metode koje ih koriste | |
| JP2012501669A5 (enExample) | ||
| JP2016526904A5 (enExample) | ||
| RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека |